# Nivolumab for Recurrent/Metastatic Carcinosarcoma

> **NCT05224999** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 28 (estimated)

## Conditions studied

- Recurrent/Metastatic Carcinosarcoma

## Interventions

- **DRUG:** nivolumab

## Key facts

- **NCT ID:** NCT05224999
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-13
- **Primary completion:** 2023-01
- **Final completion:** 2023-12
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2022-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05224999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05224999, "Nivolumab for Recurrent/Metastatic Carcinosarcoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05224999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*